Patents by Inventor Marc-Andre D'Aoust
Marc-Andre D'Aoust has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20210371472Abstract: The present invention relates to the production of modified influenza viral proteins in plants. More specifically, the present invention relates to producing and increasing influenza virus-like particle (VLP) production in plants, wherein the VLPs comprise the modified influenza viral proteins, such as modified influenza hemagglutinin (HA). The HA protein may comprising an amino acid sequence comprising at least one substitution when compared to a corresponding wildtype amino acid sequence. Further provided are nucleic acid encoding the modified HA protein. Furthermore methods of producing an influenza virus like particle (VLP) and methods of increasing yield of production of an influenza virus like particle (VLP) in a plant, portion of a plant, or a plant cell, are also provided.Type: ApplicationFiled: June 27, 2019Publication date: December 2, 2021Inventors: Pierre-Olivier LAVOIE, Aurelien LORIN, Alain DOUCET, Marc-Andre D'AOUST, Manon COUTURE
-
Publication number: 20210340184Abstract: The present invention relates to the production of modified influenza vial proteins in plants. More specifically, the present invention relates to producing and increasing influenza virus-like particle (VLP) production in plants, wherein the VLPs comprise the modified influenza viral proteins, such as modified influenza hemagglutinin (HA). The H A protein may comprising an amino acid sequence comprising at least one substitution when compared to a corresponding wildtype amino acid sequence. Further provided are nucleic acid encoding the modified H A protein. Furthermore methods of producing an influenza virus like particle (VLP) and methods of increasing yield of production of an influenza virus like particle (VLP) in a plant, portion of a plant, or a plant cell, are also provided.Type: ApplicationFiled: June 27, 2019Publication date: November 4, 2021Inventors: Pierre-Olivier LAVOIE, Aurelien LORIN, Alain DOUCET, Marc-Andre D'AOUST, Manon COUTURE
-
Patent number: 11155581Abstract: A method of producing a virus like particle (VLP) in a plant is provided. The method comprises introducing a first nucleic acid and a second nucleic acid into the plant, or portion of the plant. The first nucleic acid comprises a first regulatory region active in the plant and operatively linked to a nucleotide sequence encoding a structural virus protein. The second nucleic acid comprises a second regulatory region active in the plant and operatively linked to a nucleotide sequence encoding a channel protein, for example but not limited to a proton channel protein. The plant or portion of the plant is incubated under conditions that permit the expression of the nucleic acids, thereby producing the VLP.Type: GrantFiled: September 28, 2012Date of Patent: October 26, 2021Assignee: MEDICAGO INC.Inventors: Marc-Andre D'aoust, Manon Couture, Louis-Philippe Vezina
-
Publication number: 20210246462Abstract: An isolated expression enhancer active in a plant, portion of a plant or plant cell, the expression enhancer is provided. The isolated expression enhancer may be selected from the group consisting of nbMT78 (SEQ ID NO:1); nbATL75 (SEQ ID NO:2); nbDJ46 (SEQ ID NO:3); nbCHP79 (SEQ ID NO:4); nbEN42 (SEQ ID NO:5); atHSP69 (SEQ ID NO:6); atGRP62 (SEQ ID NO:7); atPK65 (SEQ ID NO:8); atRP46 (SEQ ID NO:9); nb30S72 (SEQ ID NO:10); nbGT61 (SEQ ID NO:11); nbPV55 (SEQ ID NO:12); nbPPI43 (SEQ ID NO:13); nbPM64 (SEQ ID NO:14); and nbH2A86 (SEQ ID NO:15). Methods for using the isolated expression enhancer are also provided.Type: ApplicationFiled: March 14, 2019Publication date: August 12, 2021Applicants: Medicago Inc., National University Corporation Nara Institute of Science and Technology, Mitsubishi TanabePhatmaCorporationInventors: Pierre-Oliver LAVOIE, Marc-Andre D'AOUST, Ko KATO, Shotaro YAMASAKI
-
Patent number: 11085049Abstract: A method of producing a virus like particle (VLP) in a plant comprising modified hemagglutinin is provided. The method comprises introducing a nucleic acid comprising a regulatory region active in the plant and operatively linked to a nucleotide sequence encoding a modified influenza hemagglutinin (HA) protein into the plant, or portion of the plant, the modified HA protein comprises a modified proteolytic loop. Followed by incubating the plant or portion of the plant under conditions that permit the expression of the nucleic acids, thereby producing the VLP. The modified proteolytic loop may comprise one or more protease cleavage sites exhibiting reduced or abolished cleavage by a protease. The nucleotide sequence encoding the HA may be selected from the group consisting of B HA, C, H1, H2, H3, H4, H5, H6, H7, H8, H9, H10, H11, H12, H13, H14, H15, and H16. Also described is a virus like particle (VLP) produced by the method, and plants expressing the VLP.Type: GrantFiled: July 19, 2019Date of Patent: August 10, 2021Assignee: MEDICAGO INC.Inventors: Manon Couture, Marc-Andre D'Aoust, Louis-Philippe Vezina
-
Publication number: 20210221853Abstract: The present invention relates to the production of modified influenza viral proteins in plants. More specifically, the present invention relates to producing and increasing influenza virus-like particle (VLP) production in plants, wherein the VLPs comprise the modified influenza viral proteins, such as modified influenza hemagglutinin (HA). The HA protein may comprising an amino acid sequence comprising at least one substitution when compared to a corresponding wildtype amino acid sequence. Further provided are nucleic acid encoding the modified HA protein. Furthermore methods of producing an influenza virus like particle (VLP) and methods of increasing yield of production of an influenza virus like particle (VLP) in a plant, portion of a plant, or a plant cell, are also provided.Type: ApplicationFiled: June 27, 2019Publication date: July 22, 2021Inventors: Pierre-Olivier LAVOIE, Aurelien LORIN, Alain DOUCET, Marc-Andre D'AOUST, Manon COUTURE
-
Publication number: 20210128714Abstract: Nucleic acids encoding modified norovirus VP1 proteins, and VLPs comprising one or more of the modified norovirus VP1 proteins are provided. Methods for modified norovirus VP1 protein, and norovirus VLP, production in plants, portions of the plant or a plant cell, are also described.Type: ApplicationFiled: November 30, 2018Publication date: May 6, 2021Applicant: MEDICAGO INC.Inventors: Marc-Andre D'AOUST, Pierre-Olivier LAVOIE
-
Publication number: 20210059142Abstract: Materials and methods are provided for making plants (e.g., Nicotiana varieties) that are suitable for producing therapeutic polypeptides suitable for administration to humans and animals, particularly by making TAL effector endonuclease-induced mutations in genes encoding xylosyltransferases and fucosyltransferases.Type: ApplicationFiled: November 13, 2020Publication date: March 4, 2021Inventors: Luc Mathis, Daniel F. Voytas, Jin Li, Feng Zhang, Thomas Stoddard, Marc-Andre D'Aoust
-
Patent number: 10907168Abstract: A method of increasing expression of an heterologous protein of interest in a plant or portion of the plant is provided. The method comprises treating the plant or portion of the plant with a jasmonate-pathway activator, and introducing a nucleotide sequence operably linked to a regulatory region derived from a DNA plant virus and encoding the heterologous protein of interest into the plant or portion of the plant. Alternatively, the plant or plant portion may comprise the nucleic acid and encoding the heterologous protein of interest, and the plant or portion of the plant is treated with the jasmonate pathway activator. The treated plant is incubated under conditions to permit expression of the nucleotide sequence encoding the heterologous protein of interest.Type: GrantFiled: June 30, 2016Date of Patent: February 2, 2021Assignees: MEDICAGO INC., UNIVERSITE LAVALInventors: Marc-Andre D'Aoust, Stephanie Robert, Marie-Claire Goulet, Dominique Michaud, Frank Sainsbury
-
Publication number: 20210023205Abstract: A method of producing a virus like particle (VLP) in a plant, and compositions comprising VLPs, are provided. The method involves introducing a nucleic acid comprising a regulatory region active in the plant and operatively linked to a chimeric nucleotide sequence encoding, in series, an ectodomain from a virus trimeric surface protein or fragment thereof, fused to an influenza transmembrane domain and cytoplasmic tail, into the plant, or portion of the plant, the ectodomain is from a non-influenza virus trimeric surface protein and heterologous with respect to the influenza transmembrane domain, and the cytoplasmic tail. The plant or portion of the plant are incubated under conditions that permit the expression of the nucleic acid, thereby producing the VLP. A VLP produced by this method are also provided.Type: ApplicationFiled: October 9, 2020Publication date: January 28, 2021Applicant: MEDICAGO INC.Inventors: Marc-Andre D'Aoust, Manon Couture, Pierre-Olivier Lavoie, Louis-Philippe Vezina
-
Publication number: 20200353071Abstract: A method of producing a virus like particle (VLP) in a plant, and compositions comprising VLPs, are provided. The method involves introducing a nucleic acid comprising a regulatory region active in the plant and operatively linked to a chimeric nucleotide sequence encoding, in series, an ectodomain from a virus trimeric surface protein or fragment thereof, fused to an influenza transmembrane domain and cytoplasmic tail, into the plant, or portion of the plant, the ectodomain is from a non-influenza virus trimeric surface protein and heterologous with respect to the influenza transmembrane domain, and the cytoplasmic tail. The plant or portion of the plant are incubated under conditions that permit the expression of the nucleic acid, thereby producing the VLP. A VLP produced by this method are also provided.Type: ApplicationFiled: March 26, 2020Publication date: November 12, 2020Applicant: MEDICAGO INC.Inventors: Marc-Andre D'Aoust, Manon Couture, Pierre-Olivier Lavoie, Louis-Philippe Vezina
-
Publication number: 20200330583Abstract: Nucleic acids encoding modified norovirus VP1 proteins, and VLPs comprising one or more of the modified norovirus VP1 proteins are provided. Methods for modified norovirus VP1 protein, and norovirus VLP, production in plants, portions of the plant or a plant cell, are also described.Type: ApplicationFiled: November 30, 2018Publication date: October 22, 2020Applicant: MEDICAGO INC.Inventors: Pierre-Olivier LAVOIE, Marc-Andre D'AOUST
-
Publication number: 20200283784Abstract: An expression enhancer comprising a CPMV 5?UTR nucleotide sequence consisting of X nucleotides (CMPVX), where X=160, 155, 150, or 114 of SEQ ID NO:1, or consisting of a nucleotide sequence comprising from about 80% to 100% sequence similarity with CMPVX, where X=160, 155, 150, or 114 of SEQ ID NO:1 SEQ ID NO:1 is provided. The expression enhancer may further comprise a stuffer sequence fused to the 3? end of the 5?UTR nucleotide sequence (CMPVX+, where X=160, 155, 150, or 114 of SEQ ID NO:1). The stuffer sequence may comprise one or more plant kozak sequences.Type: ApplicationFiled: May 21, 2020Publication date: September 10, 2020Applicant: Medicago Inc.Inventors: Pierre-Olivier LAVOIE, Marc-Andre D'AOUST
-
Publication number: 20200255849Abstract: A method of producing a virus like particle (VLP) in a plant comprising modified hemagglutinin is provided. The method comprises introducing a nucleic acid comprising a regulatory region active in the plant and operatively linked to a nucleotide sequence encoding a modified influenza hemagglutinin (HA) protein into the plant, or portion of the plant, the modified HA protein comprises a modified proteolytic loop. Followed by incubating the plant or portion of the plant under conditions that permit the expression of the nucleic acids, thereby producing the VLP. The modified proteolytic loop may comprise one or more protease cleavage sites exhibiting reduced or abolished cleavage by a protease. The nucleotide sequence encoding the HA may be selected from the group consisting of B HA, C, H1, H2, H3, H4, H5, H6, H7, H8, H9, H10, H11, H12, H13, H14, H15, and H16. Also described is a virus like particle (VLP) produced by the method, and plants expressing the VLP.Type: ApplicationFiled: July 19, 2019Publication date: August 13, 2020Applicant: MEDICAGO INC.Inventors: Manon COUTURE, Marc-Andre D'AOUST, Louis-Philippe VEZINA
-
Publication number: 20200148725Abstract: Nucleic acids encoding norovirus VP1 fusion proteins and VLPs comprising the norovirus VP1 fusion proteins are provided. Methods for norovirus VP1 fusion protein and norovirus VLP production in plants are also described. The VP1 fusion protein comprises, a first sequence encoding an S domain derived from a first norovirus strain, and a second sequence encoding a P domain derived from a second norovirus strain.Type: ApplicationFiled: March 23, 2018Publication date: May 14, 2020Applicant: MEDICAGO INC.Inventors: Pierre-Olivier LAVOIE, Marc-Andre D'AOUST
-
Patent number: 10590173Abstract: A method of producing a picornavirus-like particle (PVLP) in a plant is provided. The method comprises introducing a first nucleic acid and a second nucleic acid into the plant, portion of the plant, or a plant cell. The first nucleic acid comprising a first regulatory region active in the plant operatively linked to a nucleotide sequence encoding a polyprotein. The second nucleic acid comprises a second regulatory region active in the plant and operatively linked to a nucleotide sequence encoding one or more protease. The plant, portion of the plant, or plant cell is incubated under conditions that permit the expression of the nucleic acids, thereby producing the PVLP. A PVLP comprising the polyprotein is also provided.Type: GrantFiled: December 20, 2018Date of Patent: March 17, 2020Assignee: Medicago Inc.Inventors: Marc-Andre D'Aoust, Pierre-Olivier Lavoie, Manon Couture, Lucie Poulin, Louis-Philippe Vezina
-
Patent number: 10563213Abstract: An expression enhancer comprising, in series, a CPMV 5?UTR nucleotide sequence comprising nucleotides 1-160 of SEQ ID NO:1, or comprising a nucleotide sequence comprising from about with 80% to 100% sequence similarity with SEQ ID NO:1, and a stuffer fragment is provided. The stuffer fragment comprises a nucleotide sequence encoding an incomplete M protein and one or more kozak sequence active in a plant. Plants and plant matter comprising the expression enhancer and methods using the expression enhancer are also described.Type: GrantFiled: March 27, 2015Date of Patent: February 18, 2020Assignee: Medicago Inc.Inventors: Marc-Andre D'Aoust, Pierre-Olivier Lavoie
-
Publication number: 20190345454Abstract: A method of producing a rotavirus-like particle (RLP) in a plant is provided. The method comprises expressing within a host or host cell for example a plant, portion of a plant or plant cell one or more nucleic acid comprising one or more regulatory region operatively linked to a first, second and third nucleotide sequence, the regulatory region active in the host or host cell. The first nucleotide sequence encoding a first rotavirus protein, the second nucleotide sequence encoding a second rotavirus protein and the third nucleotide sequence encoding a third rotavirus protein. The first, second and third encode rotavirus protein NSP4 and VP2 or VP6 and VP4 or VP7. The host or host cell is incubated under conditions that permit the expression of the nucleic acids, so that NSP4 and either VP2 of VP6 and VP4 or VP7 are expressed, thereby producing the RLP. Hosts comprising the RLP, compositions comprising the RLP and method for using the composition are also provided.Type: ApplicationFiled: March 29, 2019Publication date: November 14, 2019Applicants: MEDICAGO, INC, MITSUBISHI TANABE PHARMA CORPORATIONInventors: Pierre-Olivier LAVOIE, Marc-Andre D'AOUST
-
Publication number: 20190225978Abstract: A method for synthesizing a protein of interest with a modified N-glycosylation profile within a plant, a portion of a plant, or a plant cell is provided. The method comprises co-expressing within a plant a nucleotide sequence encoding a first nucleotide sequence encoding a GDP-4-dehydro-6-deoxy-D-mannose reductase (RMD) the first nucleotide sequence operatively linked with a first regulatory region that is active in the plant, and a second nucleotide sequence encoding the protein of interest, the second nucleotide sequence operatively linked with a second regulatory region that is active in the plant. The first and second nucleotide sequences are co-expressed to synthesize a protein of interest comprising glycans with the modified N-glycosylation profile within the plant, the portion of the plant, or the plant cell.Type: ApplicationFiled: September 29, 2017Publication date: July 25, 2019Inventors: MARC-ANDRE D'AOUST, PIERRE-OLIVIER LAVOIE, ANDEOL FALCON DE LONGEVIALLE
-
Patent number: 10358652Abstract: A method of producing a virus like particle (VLP) in a plant comprising modified hemagglutinin is provided. The method comprises introducing a nucleic acid comprising a regulatory region active in the plant and operatively linked to a nucleotide sequence encoding a modified influenza hemagglutinin (HA) protein into the plant, or portion of the plant, the modified HA protein comprises a modified proteolytic loop. Followed by incubating the plant or portion of the plant under conditions that permit the expression of the nucleic acids, thereby producing the VLP. The modified proteolytic loop may comprise one or more protease cleavage sites exhibiting reduced or abolished cleavage by a protease. The nucleotide sequence encoding the HA may be selected from the group consisting of B HA, C, H1, H2, H3, H4, H5, H6, H7, H8, H9, H10, H11, H12, H13, H14, H15, and H16. Also described is a virus like particle (VLP) produced by the method, and plants expressing the VLP.Type: GrantFiled: March 28, 2014Date of Patent: July 23, 2019Assignee: MEDICAGO INC.Inventors: Manon Couture, Marc-Andre D'Aoust, Louis-Philippe Vezina